ERGIC-53 activators represent a class of compounds that play a crucial role in regulating the secretory pathway within eukaryotic cells. To understand ERGIC-53 activators, it's essential to first grasp the significance of ERGIC-53 itself. ERGIC-53, or Endoplasmic Reticulum-Golgi Intermediate Compartment protein 53, is a resident protein primarily found in the ERGIC, which is an essential component of the secretory pathway. This compartment acts as a bridge between the endoplasmic reticulum (ER) and the Golgi apparatus, facilitating the transport and processing of proteins destined for secretion. ERGIC-53 serves as a cargo receptor, specifically recognizing and binding to glycoproteins that carry the mannose-6-phosphate (M6P) signal, thereby ensuring their proper trafficking and delivery to the lysosomes.
ERGIC-53 activators are compounds that enhance the function of ERGIC-53, ultimately leading to more efficient protein trafficking within the secretory pathway. These activators typically work by increasing the affinity of ERGIC-53 for its cargo glycoproteins or by promoting its correct folding and stability. By doing so, they facilitate the sorting and transport of M6P-tagged glycoproteins to their designated cellular destinations, primarily the lysosomes. This class of compounds holds great potential for understanding the intricacies of intracellular protein trafficking and the underlying molecular mechanisms involved. Researchers studying ERGIC-53 activators aim to elucidate the ways in which these compounds can be harnessed to modulate the secretory pathway, which could have implications in various fields, including cell biology and biotechnology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin induces ER stress by inhibiting N-linked glycosylation, which could enhance ERGIC-53 expression as a cellular response. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin causes ER stress by inhibiting the ER Ca2+ ATPase, potentially upregulating ERGIC-53 as part of the unfolded protein response (UPR). | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts ER to Golgi trafficking. Cells might compensate by upregulating proteins like ERGIC-53 to restore homeostasis. | ||||||
β-Mercaptoethanol | 60-24-2 | sc-202966A sc-202966 | 100 ml 250 ml | $90.00 $120.00 | 10 | |
β-Mercaptoethanol can induce ER stress through reduction of disulfide bonds, potentially increasing ERGIC-53 levels. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
This glucose analog can lead to ER stress by hindering glycosylation processes, which might upregulate ERGIC-53 expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 inhibits the proteasome, leading to ER stress due to accumulation of misfolded proteins, possibly enhancing ERGIC-53 expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
By inhibiting lysosomal function, chloroquine can cause cellular stress, which may incidentally increase ERGIC-53 expression. | ||||||
4-Phenylbutyric acid | 1821-12-1 | sc-232961 sc-232961A sc-232961B | 25 g 100 g 500 g | $53.00 $136.00 $418.00 | 10 | |
This chemical chaperone can reduce ER stress and might upregulate ERGIC-53 expression to facilitate protein folding and trafficking. | ||||||
Sodium phenylbutyrate | 1716-12-7 | sc-200652 sc-200652A sc-200652B sc-200652C sc-200652D | 1 g 10 g 100 g 1 kg 10 kg | $77.00 $166.00 $622.00 $5004.00 $32783.00 | 43 | |
Similar to its acid form, this compound acts as a chaperone that could influence ERGIC-53 levels by modulating protein trafficking. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium has been shown to affect various signaling pathways and could indirectly upregulate ERGIC-53 expression. | ||||||